AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29449080 — intervention group
Group type: COMPARATOR
Intervention: Submaximal LEG exercise
Number of subjects: 13
Study 29449080 — intervention group
Group type: COMPARATOR
Intervention: Submaximal ARM exercise
Number of subjects: 13
Study 26635335 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking program (Ti-To; n = 18)
Number of subjects: 27
Study 26635335 — intervention group
Group type: COMPARATOR
Intervention: Revascularization (Rev; n = 9)
Number of subjects: 27
Study 24756483 — intervention group
Group type: EXPERIMENTAL
Intervention: 2g omega-3 PUFA daily, initiated 5 days before surgery
Number of subjects: 198
Study 24756483 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with omega-3 PUFA)
Number of subjects: 198
Study 22621326 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% oxygen
Number of subjects: 200
Study 22621326 — intervention group
Group type: COMPARATOR
Intervention: 65% oxygen
Number of subjects: 200
Study 20570818 — intervention group
Group type: EXPERIMENTAL
Intervention: Real TMS
Number of subjects: 0
Study 20570818 — intervention group
Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 0
Study 20570818 — intervention group
Group type: COMPARATOR
Intervention: No TMS
Number of subjects: 0
Study 20570818 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprathreshold TMS on M1
Number of subjects: 0
Study 20570818 — intervention group
Group type: COMPARATOR
Intervention: Subthreshold TMS over M1
Number of subjects: 0
Study 20570818 — intervention group
Group type: COMPARATOR
Intervention: Peripheral arm stimulation
Number of subjects: 0
Study 18310475 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 44
Study 16555574 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (40‐80 mg)
Number of subjects: 22
Study 16555574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 12438003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dental technicians (exposed to chromium, cobalt, and nickel)
Number of subjects: 27
Study 12438003 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (not exposed)
Number of subjects: 27
Study 10526740 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch biographer glucose measurements in a controlled outpatient clinic setting
Number of subjects: 28
Study 10526740 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch biographer glucose measurements in a home setting
Number of subjects: 28
Study 10526740 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch biographer glucose measurements (two biographers worn simultaneously)
Number of subjects: 28
Study 10526740 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch biographer glucose values
Number of subjects: 28
Study 7732799 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulprostone (prostaglandin E2 analogue)
Number of subjects: 81
Study 7732799 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin and ergometrine (control group)
Number of subjects: 81
Study 1974669 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 0
Study 1974669 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 0
Study 1974669 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study 1974669 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol
Number of subjects: 0
Study 1974669 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 1974669 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 0
Study 1974669 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil, Ketotifen, Cromolyn
Number of subjects: 0
Study 394576 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC (Vincristine, Adriamycin, Cyclophosphamide)
Number of subjects: 64
Study 394576 — intervention group
Group type: COMPARATOR
Intervention: VACM (VAC with Methotrexate and citrovorum factor rescue)
Number of subjects: 64
Study 394576 — intervention group
Group type: EXPERIMENTAL
Intervention: VAC
Number of subjects: 64
Study 394576 — intervention group
Group type: COMPARATOR
Intervention: VACM
Number of subjects: 64
Study 31811715 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg or 90 mg plus aspirin
Number of subjects: 4199
Study 31811715 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin
Number of subjects: 4199
Study 31662524 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/day solifenacin
Number of subjects: 96
Study 31662524 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral uterosacral ligament replacement, cervicosacropexy, or vaginosacropexy
Number of subjects: 96
Study 28025862 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HDL-C at 36 weeks gestation
Number of subjects: 320
Study 28025862 — intervention group
Group type: COMPARATOR
Intervention: Low HDL-C at 36 weeks gestation
Number of subjects: 320
Study 28025862 — intervention group
Group type: COMPARATOR
Intervention: Low low-density lipoprotein cholesterol at 36 weeks gestation
Number of subjects: 320
Study 25955579 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified triangular cord thickness and gallbladder classification scheme
Number of subjects: 273
Study 25955579 — intervention group
Group type: COMPARATOR
Intervention: Triangular cord thickness alone
Number of subjects: 273
Study 23490379 — intervention group
Group type: EXPERIMENTAL
Intervention: albIFN 900/1200/1500 μg q4wk
Number of subjects: 391
Study 23490379 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFNα‐2a 180 μg qwk
Number of subjects: 391
Study 23490379 — intervention group
Group type: EXPERIMENTAL
Intervention: oral ribavirin 800 mg/d
Number of subjects: 391
Study 23490379 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 391
Study 21289240 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (4000 mg Disalsid)
Number of subjects: 9
Study 21289240 — intervention group
Group type: COMPARATOR
Intervention: Intralipid
Number of subjects: 9
Study 19729945 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (BUD) for 4 weeks
Number of subjects: 30
Study 19729945 — intervention group
Group type: COMPARATOR
Intervention: No budesonide treatment (Control)
Number of subjects: 30
Study 17239709 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 125
Study 17239709 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 125
Study 17239709 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin + Pioglitazone (Combination)
Number of subjects: 125
Study 15278753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral enzyme‐rutosid combination (ERC)
Number of subjects: 103
Study 15278753 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 103
Study 15278753 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 103
Study 11602473 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional job training, equal career opportunities, letting the disease influence the choice of the current job position, informing colleagues about having the disease
Number of subjects: 720
Study 11602473 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusting job demands
Number of subjects: 720
Study 11602473 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing activities and diverting attention to cope with pain, pacing to cope with limitations
Number of subjects: 720
Study 11602473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing
Number of subjects: 720
Study 9236354 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonpulsatile hypothermic (NP 28)
Number of subjects: 24
Study 9236354 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile normothermic (P 37)
Number of subjects: 24
Study 9236354 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 24
Study 9236354 — intervention group
Group type: COMPARATOR
Intervention: Total-body oxygen consumption and extraction
Number of subjects: 24
Study 7525170 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 1104
Study 7525170 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult diabetic patients
Number of subjects: 1104
Study 7525170 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 258)
Number of subjects: 1104
Study 7525170 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated adult diabetic patients
Number of subjects: 1104
Study 7525170 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-treated adult diabetic patients
Number of subjects: 1104
Study 7525170 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 1104
Study 7525170 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated HbF
Number of subjects: 1104
Study 3311105 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 1% indomethacin
Number of subjects: 0
Study 3311105 — intervention group
Group type: COMPARATOR
Intervention: Previous studies
Number of subjects: 0
Study 29701043 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus clomiphene (electroacupuncture applied 30 min, continuous wave, 2 Hz, 3 times a week for 3 months)
Number of subjects: 80
Study 29701043 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene (oral administration for 5 days starting from the 5th day of menstruation or medicine-withdrawal bleeding)
Number of subjects: 80
Study 26670575 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator tape (TOT)
Number of subjects: 176
Study 26670575 — intervention group
Group type: COMPARATOR
Intervention: Retropubic tension-free vaginal tape (TVT)
Number of subjects: 176
Study 25576351 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease management programs (DMPs) for 6 months including self-management education provided by a nurse and support from primary care physician
Number of subjects: 321
Study 25576351 — intervention group
Group type: COMPARATOR
Intervention: Usual care (ordinary outpatient care)
Number of subjects: 321
Study 23613786 — intervention group
Group type: EXPERIMENTAL
Intervention: MST+YOT
Number of subjects: 108
Study 23613786 — intervention group
Group type: COMPARATOR
Intervention: YOT alone
Number of subjects: 108
Study 20525993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 846
Study 20525993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 400 mg twice daily
Number of subjects: 846
Study 20525993 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 846
Study 18845704 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium chain triglyceride (MCT) oil
Number of subjects: 31
Study 18845704 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 31
Study 16635175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive asthma education program (group B)
Number of subjects: 100
Study 16635175 — intervention group
Group type: COMPARATOR
Intervention: Standard asthma education program (group A)
Number of subjects: 100
Study 12482789 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose lisinopril (32.5 or 35 mg)
Number of subjects: 3164
Study 12482789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose lisinopril (2.5 or 5 mg)
Number of subjects: 3164
Study 12482789 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of beta blockers or antiarrhythmic agents (mainly amiodarone)
Number of subjects: 3164
Study 12482789 — intervention group
Group type: EXPERIMENTAL
Intervention: Long acting nitrates and previous use of angiotensin converting enzyme inhibitors
Number of subjects: 3164
Study 12482789 — intervention group
Group type: EXPERIMENTAL
Intervention: Low systolic blood pressure at baseline, raised creatinine, reduced serum sodium or haemoglobin, and increased heart rate
Number of subjects: 3164
Study 10658074 — intervention group
Group type: EXPERIMENTAL
Intervention: Open cholecystectomy (OC)
Number of subjects: 28
Study 10658074 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 28
Study 8691702 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchiectomy plus diethylstilbestrol diphosphate
Number of subjects: 39
Study 8691702 — intervention group
Group type: COMPARATOR
Intervention: Orchiectomy plus diethylstilbestrol diphosphate plus combination chemotherapy with cisplatin and methotrexate
Number of subjects: 39
Study 1379883 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of risperidone daily
Number of subjects: 0
Study 1379883 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of haloperidol
Number of subjects: 0
Study 6381185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 1.2 g/day
Number of subjects: 105
Study 6381185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 2.4 g/day
Number of subjects: 105
Study 6381185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 30742555 — intervention group
Group type: EXPERIMENTAL
Intervention: Lettuce harvested from Verticillium-infested fields
Number of subjects: 22
Study 28551775 — intervention group
Group type: EXPERIMENTAL
Intervention: LBEC0101
Number of subjects: 48
Study 28551775 — intervention group
Group type: COMPARATOR
Intervention: Enbrel®
Number of subjects: 48
Study 26554773 — intervention group
Group type: EXPERIMENTAL
Intervention: MRC group (13 patients)
Number of subjects: 23
Study 26554773 — intervention group
Group type: COMPARATOR
Intervention: Surgery group (10 patients)
Number of subjects: 23
Study 23023996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelviva(®) plus unsupervised pelvic floor muscle exercise
Number of subjects: 123
Study 23023996 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised pelvic floor muscle exercise alone
Number of subjects: 123
Study 21059615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy
Number of subjects: 332
Study 21059615 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention-control education
Number of subjects: 332
Study 21059615 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 332
Study 20426279 — intervention group
Group type: EXPERIMENTAL
Intervention: SMT + AO
Number of subjects: 53
Study 20426279 — intervention group
Group type: COMPARATOR
Intervention: SMT
Number of subjects: 53
Study 17196973 — intervention group
Group type: EXPERIMENTAL
Intervention: Relevant questions related to bridging inference
Number of subjects: 32
Study 17196973 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant questions related to bridging inference
Number of subjects: 32
Study 17196973 — intervention group
Group type: COMPARATOR
Intervention: Adolescents with autism
Number of subjects: 32
Study 17196973 — intervention group
Group type: COMPARATOR
Intervention: Normally developing adolescents
Number of subjects: 32
Study 15013543 — intervention group
Group type: EXPERIMENTAL
Intervention: Condyles positioned in the centre of the articular fossa before and during the operation (14 patients, 28 TMJs)
Number of subjects: 28
Study 15013543 — intervention group
Group type: COMPARATOR
Intervention: Condyles not positioned in the centre of the articular fossa (14 patients, 28 TMJs)
Number of subjects: 28
Study 11759022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium (liquid alcoholic rub-in hand disinfectant)
Number of subjects: 15
Study 11759022 — intervention group
Group type: COMPARATOR
Intervention: Hibiscrub (water-based handwashing antiseptic)
Number of subjects: 15
Study 11759022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterillium
Number of subjects: 15
Study 11759022 — intervention group
Group type: COMPARATOR
Intervention: Hibiscrub
Number of subjects: 15
Study 11759022 — intervention group
Group type: COMPARATOR
Intervention: Alcoholic gels
Number of subjects: 15
Study 9781721 — intervention group
Group type: EXPERIMENTAL
Intervention: cA2 (300 mg single dose)
Number of subjects: 56
Study 9781721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7878557 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium (4 mg) four times daily
Number of subjects: 50
Study 7878557 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 3226339 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of ethinyl oestreadiol (EE)
Number of subjects: 24
Study 3226339 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of oestradiol valerate (E2V)
Number of subjects: 24
Study 31188700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic Preconditioning (IPC)
Number of subjects: 16
Study 31188700 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 16
Study 31188700 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study 28347183 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional intervention aimed at improving social support during the transition from inpatient to outpatient care provided by a social worker
Number of subjects: 151
Study 28347183 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 151
Study 25697124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress management (MBSM/Mindful-Gym) program
Number of subjects: 75
Study 25697124 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 23506163 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-PLUS stem
Number of subjects: 8
Study 23506163 — intervention group
Group type: EXPERIMENTAL
Intervention: BetaCone stem
Number of subjects: 8
Study 23506163 — intervention group
Group type: COMPARATOR
Intervention: Reference group (normal healthy hip)
Number of subjects: 8
Study 21439048 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg
Number of subjects: 200
Study 21439048 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide 40 mg
Number of subjects: 200
Study 17600772 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-tailored after-school dance program and home/family-based intervention to reduce screen media use
Number of subjects: 261
Study 17600772 — intervention group
Group type: COMPARATOR
Intervention: Information-based community health education Active-Placebo Comparison intervention
Number of subjects: 261
Study 17139218 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (short-segment posterior stabilization)
Number of subjects: 34
Study 17139218 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 34
Study 14514368 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment (Group B)
Number of subjects: 372
Study 14514368 — intervention group
Group type: COMPARATOR
Intervention: Surgical operation only (Group A)
Number of subjects: 372
Study 11192518 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate supplementation (1 mg/kg per day)
Number of subjects: 16
Study 11192518 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (Control)
Number of subjects: 16
Study 9355191 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulated vitrectomy system
Number of subjects: 77
Study 9355191 — intervention group
Group type: COMPARATOR
Intervention: Noncannulated group
Number of subjects: 77
Study 8472516 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablets (600 mg of ST‐679)
Number of subjects: 0
Study 8472516 — intervention group
Group type: COMPARATOR
Intervention: Envelopes (600 mg of ST‐679)
Number of subjects: 0
Study 2433901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40 (500 ml on admission and on days 1 and 2; 250 ml on days 4 and 6)
Number of subjects: 50
Study 2433901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dextran or venesection)
Number of subjects: 50
Study 2433901 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40
Number of subjects: 50
Study 2433901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 29943239 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation (tACS) at individual alpha peak frequency (1.5 mA for 10 min)
Number of subjects: 0
Study 29943239 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26610167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialogical Exposure Therapy (DET)
Number of subjects: 141
Study 26610167 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 141
Study 24987174 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil 25 mg, administered eight hourly for 24 hours before surgery (N = 20)
Number of subjects: 40
Study 24987174 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 20)
Number of subjects: 40
Study 24987174 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil 25 mg
Number of subjects: 40
Study 24987174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22570428 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 60 mg taken up to 3 times daily
Number of subjects: 50
Study 22570428 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 50
Study 19890257 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stressor (Trier social stress test (TSST))
Number of subjects: 102
Study 19890257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 102
Study 19890257 — intervention group
Group type: COMPARATOR
Intervention: Beta-adrenoceptor antagonist propranolol
Number of subjects: 102
Study 19890257 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol with propranolol, cortisol alone, or propranolol alone
Number of subjects: 102
Study 19890257 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress or cortisol
Number of subjects: 102
Study 18806024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal remifentanil (4 mcg/kg)
Number of subjects: 188
Study 18806024 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 188
Study 15664480 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (2000/125 mg), given twice daily
Number of subjects: 351
Study 15664480 — intervention group
Group type: COMPARATOR
Intervention: Conventional amoxicillin/clavulanate formulations (control)
Number of subjects: 351
Study 15664480 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (2000/125 mg) for PRSP-infected patients
Number of subjects: 351